Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial4. (4th October 2013)

• Record Type: Journal Article
• Authors: Skorupski, K. A.; Uhl, J. M.; Szivek, A.; Allstadt Frazier, S. D.; Rebhun, R. B.; Rodriguez, C. O.
• Is Part Of: Veterinary and comparative oncology. Volume 14:Number 1(2016:Mar.)
• Page Start: 81
• Page End: 87
• Publication Date: 2013-10-04
• Subjects: amputation -- bone tumour -- canine -- chemotherapy -- clinical trial; Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12069
• Languages: English
• ISSNs: 1476-5810

Abstract

Abstract: Despite numerous published studies describing adjuvant chemotherapy for canine appendicular osteosarcoma, there is no consensus as to the optimal chemotherapy protocol. The purpose of this study was to determine whether either of two protocols would be associated with longer disease‐free interval (DFI) in dogs with appendicular osteosarcoma following amputation. Dogs with histologically confirmed appendicular osteosarcoma that were free of gross metastases and underwent amputation were eligible for enrollment. Dogs were randomized to receive either six doses of carboplatin or three doses each of carboplatin and doxorubicin on an alternating schedule. Fifty dogs were included. Dogs receiving carboplatin alone had a significantly longer DFI (425 versus 135 days) than dogs receiving alternating carboplatin and doxorubicin ( P = 0.04). Toxicity was similar between groups. These results suggest that six doses of carboplatin may be associated superior DFI when compared to six total doses of carboplatin and doxorubicin.